Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (5191)
Dr. Jennifer Sauter is an Assistant Attending Pathologist in Thoracic Pathology and Cytopathology at Memorial Sloan Kettering Cancer Center. Her research interests are in pleural tumors as well as non small cell lung carcinoma and other tumors of the thorax. Most recently, she served as the lead author of the Diffuse Pleural Mesothelioma Section in the 2021 World Health Organization Classification of Thoracic Tumors.
Published in
Speakers
Suresh Senan is Professor of clinical experimental radiotherapy at the Amsterdam University Medical Centers, The Netherlands. He trained in clinical oncology in the United Kingdom before moving to the Netherlands. His research has focused on lung cancer, stereotactic radiotherapy, immune checkpoint inhibitors, and Magnetic Resonance-guided adaptive radiotherapy. In 2016, he was awarded the Heine H. Hansen Award for his contributions to lung cancer care by the European Society of Medical Oncology and International Association for the Study of Lung Cancer.
Published in
Speakers
Dr Paul Mitchell holds the positions of Medical Oncologist at the Olivia Newton-John Cancer, Wellness and Research Centre at Austin Health in Melbourne, Australia, Director of the North-Eastern Melbourne Integrated Cancer Service (Cancer Network) and Associate Professor at the University of Melbourne and University of Sydney. He is immediate past-President of the Australasian Lung Cancer Trials Group 2012-2016. He is Chair of the Lung Cancer Advisory Group of Cancer Australia, sits on the State Government’s Clinical Council and the Program Assessing Committee of the Health Research Council of New Zealand.
Dr Mitchell trained in medical oncology in Auckland, New Zealand, followed by two years as Senior Registrar at the Royal Marsden Hospital, UK, before completing a Doctor of Medicine degree based on 3 years work at the Institute of Cancer Research, UK. He moved to Melbourne in 1995.
Dr Mitchell trained in medical oncology in Auckland, New Zealand, followed by two years as Senior Registrar at the Royal Marsden Hospital, UK, before completing a Doctor of Medicine degree based on 3 years work at the Institute of Cancer Research, UK. He moved to Melbourne in 1995.
Published in
Speakers
Puneeth Iyengar is an Associate Professor and Chief of Thoracic Radiation Oncology at UT Southwestern Medical Center. He is also Associate Vice Chair for Research for the Department of Radiation Oncology and Co Leader of the Thoracic Program at UTSW. He has led programs investigating the use of local therapy (SBRT) in the setting of oligometastatic NSCLC (Iyengar et al, JCO 2014, Iyengar et al, JAMA Oncology 2017), hypofractionated therapies for stage III NSCLC (Iyengar et al, JAMA Oncology 2021) and is principal investigator of NRG LU 002, a phase III randomized trial assessing the benefits of local therapy on overall survival for stage IV NSCLC. Dr. Iyengar also runs an independent research laboratory studying cancer cachexia from a basic science and translational perspective. Dr. Iyengar trained at MD Anderson Cancer Center and received his MD, PhD degrees at Albert Einstein College of Medicine (NYC) and Bachelor of Science at MIT.
Published in
Speakers
Dr. Nasser K. Altorki is the Chief of the Division of Thoracic Surgery at the New York-Presbyterian Hospital and is the David B. Skinner Professor of Cardiothoracic Surgery at Weill Cornell Medical College. He is also leader of the Experimental Therapeutics Program at the Sandra and Edward Meyer Cancer Center and Director of the Neuberger Berman Lung Cancer Research Center. Dr. Altorki completed his surgical and cardiothoracic training at the University of Chicago and joined the faculty at Weill Cornell Medicine in 1988. His professional interests include: the surgical treatment of esophageal and lung cancer, minimally invasive surgical techniques, and clinical trials in lung and esophageal cancer. Beyond his expertise in the surgical treatment of lung cancer and other chest malignancies, he has a longstanding interest in studying the immune landscape as well as immunotherapy for early stage lung cancer and has led several trials of adjuvant and neoadjuvant immunotherapy in early stage lung cancer. Dr. Altorki has served as the principle investigator on a number of national and international clinical trials, and has written numerous manuscripts and book chapters on lung cancer screening, staging and management of early lung cancer.
In 2007, Dr. Altorki established the Neuberger Berman Lung Cancer Research Program at Weill Cornell Medicine to support laboratory -based translational lung cancer research. The program’s primary objective is to explore the role of the tumor immune microenvironment in the initiation and progression of lung cancer. Over the years this program has matured and expanded to include four principal investigators. Dr. Altorki is also a member of numerous professional organizations, including the IASLC, the American Society of Clinical Oncology, the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American College of Surgeons, and the American Association of Cancer Research. Last, but not least, Dr. Altorki is a passionate patient advocate and thoughtful teacher and mentor to many residents, fellows, and junior faculty.
In 2007, Dr. Altorki established the Neuberger Berman Lung Cancer Research Program at Weill Cornell Medicine to support laboratory -based translational lung cancer research. The program’s primary objective is to explore the role of the tumor immune microenvironment in the initiation and progression of lung cancer. Over the years this program has matured and expanded to include four principal investigators. Dr. Altorki is also a member of numerous professional organizations, including the IASLC, the American Society of Clinical Oncology, the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American College of Surgeons, and the American Association of Cancer Research. Last, but not least, Dr. Altorki is a passionate patient advocate and thoughtful teacher and mentor to many residents, fellows, and junior faculty.
Published in
Speakers
Dr. Ross Soo is a senior consultant in the Department of Haematology-Oncology at the National University Cancer Institute Singapore, and an adjunct principal investigator at the Cancer Science Institute of Singapore, National University of Singapore. He received his medical degree from Monash University, underwent specialist training in Melbourne and Sydney, and subsequently became a fellow of the Royal Australasian College of Physicians and the Academy of Medicine, Singapore. He specialises in lung cancer and head and neck cancer and leads the lung tumour group at the National University Cancer Institute, Singapore.
Dr. Soo’s professional affiliations include memberships of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Singapore Society of Oncology. He sits on various committees including National Healthcare Group Domain-Specific Ethics Review Board, Ministry of Health Drug Advisory Committee (DAC), DAC-Oncology Drug Subcommittee, Medical Oncology Specialist Training Committee, Chapter of Medical Oncology Executive Committee, and the International Association for the Study of Lung Cancer Communications Committee.
Dr. Soo’s professional affiliations include memberships of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Singapore Society of Oncology. He sits on various committees including National Healthcare Group Domain-Specific Ethics Review Board, Ministry of Health Drug Advisory Committee (DAC), DAC-Oncology Drug Subcommittee, Medical Oncology Specialist Training Committee, Chapter of Medical Oncology Executive Committee, and the International Association for the Study of Lung Cancer Communications Committee.
Published in
Speakers
Max Diehn received his undergraduate degree in Biochemical Sciences from Harvard College and his M.D./Ph.D. from Stanford University in 2004. He subsequently completed radiation oncology residency at Stanford in 2009. He then joined the faculty and currently is the CRK Faculty Scholar and Associate Professor, Division Chief of Radiation and Cancer Biology, and Vice Chair of Research in the Department of Radiation Oncology.
Dr. Diehn is a physician scientist and practicing radiation oncologist who specializes in the treatment of lung cancer. His research program spans laboratory, translational, and clinical studies. The majority of his research efforts are focused on the development and application of liquid biopsy technologies for cancer screening, treatment response assessment, and detection of minimal residual disease. His group also studies mechanisms of resistance to radiotherapy, immunotherapy and targeted therapies.
Dr. Diehn has served on committees for a number of national and international organizations including IASLC, NCI, ASCO, and AACR. He is a Scientific Editor for Cancer Discovery and serves on the Thoracic Malignancies Steering Committee of the NCI. He has participated in ESMO’s Translational Research & Precision Medicine Working Group project on liquid biopsies. Dr. Diehn has been recognized with a variety of awards, including the NIH Director’s New Innovator Award, the V Foundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris Duke Clinical Scientist Development Award, and election into the American Society for Clinical Investigation.
Dr. Diehn is a physician scientist and practicing radiation oncologist who specializes in the treatment of lung cancer. His research program spans laboratory, translational, and clinical studies. The majority of his research efforts are focused on the development and application of liquid biopsy technologies for cancer screening, treatment response assessment, and detection of minimal residual disease. His group also studies mechanisms of resistance to radiotherapy, immunotherapy and targeted therapies.
Dr. Diehn has served on committees for a number of national and international organizations including IASLC, NCI, ASCO, and AACR. He is a Scientific Editor for Cancer Discovery and serves on the Thoracic Malignancies Steering Committee of the NCI. He has participated in ESMO’s Translational Research & Precision Medicine Working Group project on liquid biopsies. Dr. Diehn has been recognized with a variety of awards, including the NIH Director’s New Innovator Award, the V Foundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris Duke Clinical Scientist Development Award, and election into the American Society for Clinical Investigation.
Published in
Speakers
Prof. Rolfo is the Associate Director of Clinical Research at the Center for Thoracic Oncology, Tisch Cancer Institute in Mount Sinai System . In addition, he is Professor of Medicine at the Division of Hematology and Oncology at Icahn School of Medicine, Mount Sinai, New York, NY, USA.
From April 2018 to May 2021 he was serving as Director of Thoracic Medical Oncology and Director of Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), in Baltimore, Maryland, USA. In addition, he was appointed Professor of Medicine at the Division of Oncology at Maryland University, School of Medicine. Prof. Rolfo is Medical Oncologist focused in Thoracic Oncology, Drug Development and Translational Oncology.
From 2012 to March 2018 he was working as Director of the Phase I - Early Clinical Trials Unit, Director of the Clinical Trials Management Program at Antwerp University Hospital, and Senior Staff member of Thoracic Oncology Cluster at Antwerp University Hospital in Belgium. In addition he is Professor of Oncology at Antwerp University in the Center for Oncological Research (CORE) in Antwerp, Belgium,
Professor Rolfo graduated with a degree in medicine from the National University of Córdoba, Argentina in 1996; he then studied at the University of Milan and the National Cancer Institute of Milan, Italy, receiving European Oncology Board certification in 2003, followed by Spanish Board Certification in Medical Oncology in 2007. He obtained a PhD and Doctor Europaeus in Clinical and Experimental Oncology Research cum laude from the University of Palermo, Italy in 2009 under the direction of Professor Rosell, and a Master of Business Health Administration from the Polytechnic University of Valencia, Spain in 2010. He worked as clinical researcher in the Spanish Lung Cancer Group in Mallorca, Spain for 8 years.
He is actively working on drug development and Lung cancer & Mesothelioma treatment. His research is focused in molecular oncology and Immunotherapy in Thoracic Oncology and in a pan-tumoral approach, using new techniques in liquid biopsies, specifically in exosome isolation and circulating free tumour DNA. His group identify ALK translocation in exosomes in NSCLC patients, showed, for the first time, the videos of labeled EVs uptake by living lung cancer cells. He is currently working in the identification of new biomarkers involved in immunotherapy and TKI drug-resistance. In Drug development Prof. Rolfo contributed to the development of several compounds including Erlotinib, pharmacokinetics of Olaparib, Entrectinib among several drugs in early phase.
Prof. Rolfo served as an expert member of the Commission for Medicinal Products for Human Use and First in Human Drugs Commission at the Federal Agency of Health and Medicinal Products from Belgium and external expert for the European Agency of Medicine (EMA).
Professor Rolfo is the Deputy Chair of the educational committee at the International Association for the Study of Lung Cancer (IASLC), served on the membership committee of ESMO, is the current vice-president of the International Society of Liquid Biopsy (ISLB) and member of the American Society of Clinical Oncology (ASCO), American Society of Clinical Research (AACR) the Oncology Latin-American Association (OLA) and other prestigious societies. He has been the recipient of numerous professional accolades, including an Honorary Doctorate by UPSJB in Peru as well Visiting Professor in Saudi Arabia, Italy and Distinguish Professor by his Alma mater University in Argentina. He has been a speaker at national and international forums in lung cancer, liquid biopsy and drug development, and has published extensively in peer-reviewed journals including New England Journal of Medicine, Lancet Oncology, Cancer Discovery, Nature Nanotechnology, Clinical Cancer Research, Annals of Oncology, and Lung Cancer among others. Prof. Rolfo is Editor in Chief of Critical Review in Oncology Hematology.
From April 2018 to May 2021 he was serving as Director of Thoracic Medical Oncology and Director of Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), in Baltimore, Maryland, USA. In addition, he was appointed Professor of Medicine at the Division of Oncology at Maryland University, School of Medicine. Prof. Rolfo is Medical Oncologist focused in Thoracic Oncology, Drug Development and Translational Oncology.
From 2012 to March 2018 he was working as Director of the Phase I - Early Clinical Trials Unit, Director of the Clinical Trials Management Program at Antwerp University Hospital, and Senior Staff member of Thoracic Oncology Cluster at Antwerp University Hospital in Belgium. In addition he is Professor of Oncology at Antwerp University in the Center for Oncological Research (CORE) in Antwerp, Belgium,
Professor Rolfo graduated with a degree in medicine from the National University of Córdoba, Argentina in 1996; he then studied at the University of Milan and the National Cancer Institute of Milan, Italy, receiving European Oncology Board certification in 2003, followed by Spanish Board Certification in Medical Oncology in 2007. He obtained a PhD and Doctor Europaeus in Clinical and Experimental Oncology Research cum laude from the University of Palermo, Italy in 2009 under the direction of Professor Rosell, and a Master of Business Health Administration from the Polytechnic University of Valencia, Spain in 2010. He worked as clinical researcher in the Spanish Lung Cancer Group in Mallorca, Spain for 8 years.
He is actively working on drug development and Lung cancer & Mesothelioma treatment. His research is focused in molecular oncology and Immunotherapy in Thoracic Oncology and in a pan-tumoral approach, using new techniques in liquid biopsies, specifically in exosome isolation and circulating free tumour DNA. His group identify ALK translocation in exosomes in NSCLC patients, showed, for the first time, the videos of labeled EVs uptake by living lung cancer cells. He is currently working in the identification of new biomarkers involved in immunotherapy and TKI drug-resistance. In Drug development Prof. Rolfo contributed to the development of several compounds including Erlotinib, pharmacokinetics of Olaparib, Entrectinib among several drugs in early phase.
Prof. Rolfo served as an expert member of the Commission for Medicinal Products for Human Use and First in Human Drugs Commission at the Federal Agency of Health and Medicinal Products from Belgium and external expert for the European Agency of Medicine (EMA).
Professor Rolfo is the Deputy Chair of the educational committee at the International Association for the Study of Lung Cancer (IASLC), served on the membership committee of ESMO, is the current vice-president of the International Society of Liquid Biopsy (ISLB) and member of the American Society of Clinical Oncology (ASCO), American Society of Clinical Research (AACR) the Oncology Latin-American Association (OLA) and other prestigious societies. He has been the recipient of numerous professional accolades, including an Honorary Doctorate by UPSJB in Peru as well Visiting Professor in Saudi Arabia, Italy and Distinguish Professor by his Alma mater University in Argentina. He has been a speaker at national and international forums in lung cancer, liquid biopsy and drug development, and has published extensively in peer-reviewed journals including New England Journal of Medicine, Lancet Oncology, Cancer Discovery, Nature Nanotechnology, Clinical Cancer Research, Annals of Oncology, and Lung Cancer among others. Prof. Rolfo is Editor in Chief of Critical Review in Oncology Hematology.
Published in
Speakers
Dr. Maria Arcila is a molecular pathologist and is the director of the Diagnostic Molecular Pathology Laboratory at Memorial Sloan Kettering Cancer Center. Her practice focuses on the development and validation of technology to determine the genetic characteristics of tumors which can then be utilized as markers for disease diagnosis, treatment, risk assessment and longitudinal monitoring. She has a specific interest in the assessment of genetic markers using liquid biopsies and tumor tissues obtained through minimally invasive procedures, with an extensive publication history based on this technology. Dr. Arcila has served in multiple committees to establish guidelines of the use of molecular markers and techniques for the study of cancer including the CAP/IASLC/AMP Molecular Testing Guideline for lung cancer and the Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels.
Published in
Speakers
Dr Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, and is Professor in the Department of Medicine, and Adjunct Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto. She holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development through the Princess Margaret Cancer Foundation. She has published over 300 peer-reviewed papers, has held (as principal or co-investigator) over $60 million in peer-reviewed grant funding, and has mentored many oncology trainees that have gone on to leadership roles in oncology around the world. In 2019, she was awarded the American Society of Clinical Oncology Excellence in Teaching Award).
Dr Leighl’s main interest is in developing new treatments in lung cancer and improving lung cancer diagnostics. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, has led several international and cooperative group studies in lung cancer and has served as a member of the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group. She was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 World Conference in Lung Cancer, and serves on multiple committees including the ASCO Thoracic Guidelines Advisory Group, ESMO Scientific and Educational Committees (Metastatic Lung Track), is co-section editor of The Oncologist and Current Oncology, an editorial board member of the Journal of Thoracic Oncology, British Journal of Cancer, a member of the IASLC Quality and Value Committee, on the Scientific Advisory Board of the Lung Cancer Foundation of America, and was recently elected to the Board of Directors of the Americas Health Foundation. Previously she served as Web Editor of the Journal of Thoracic Oncology, on the editorial board of the Journal of Clinical Oncology, the Royal College of Physicians & Surgeons of Canada Medical Oncology Examination Board, and is Past President of Lung Cancer Canada.
Dr Leighl’s main interest is in developing new treatments in lung cancer and improving lung cancer diagnostics. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, has led several international and cooperative group studies in lung cancer and has served as a member of the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group. She was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 World Conference in Lung Cancer, and serves on multiple committees including the ASCO Thoracic Guidelines Advisory Group, ESMO Scientific and Educational Committees (Metastatic Lung Track), is co-section editor of The Oncologist and Current Oncology, an editorial board member of the Journal of Thoracic Oncology, British Journal of Cancer, a member of the IASLC Quality and Value Committee, on the Scientific Advisory Board of the Lung Cancer Foundation of America, and was recently elected to the Board of Directors of the Americas Health Foundation. Previously she served as Web Editor of the Journal of Thoracic Oncology, on the editorial board of the Journal of Clinical Oncology, the Royal College of Physicians & Surgeons of Canada Medical Oncology Examination Board, and is Past President of Lung Cancer Canada.
Published in
Speakers
